Prometic Life Sciences Inc., of Laval, Quebec, said the drug safety monitoring board recommended that patient enrollment should continue in the company's Alström syndrome phase II trial. This recommendation follows the board's review of the safety data accumulated in the first eight Alström syndrome patients that had received treatment with PBI-4050.